AR089939A1 - COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 - Google Patents
COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1Info
- Publication number
- AR089939A1 AR089939A1 ARP130100396A AR089939A1 AR 089939 A1 AR089939 A1 AR 089939A1 AR P130100396 A ARP130100396 A AR P130100396A AR 089939 A1 AR089939 A1 AR 089939A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- cycloalkyl
- alkyl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) y sales farmacéuticamente aceptables de estos, como inhibidores de mPGES-1. Estos compuestos son inhibidores de la enzima prostaglandina E1 sintasa microsomal (mPGES-1) y por lo tanto son útiles en el tratamiento de dolor y/o inflamación de una variedad de enfermedades o afecciones, tales como asma, osteoartritis, artritis reumatoide, dolor agudo o crónico y enfermedades neurodegenerativas. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de este, donde Y es O, NH o NRᶜ; Z¹ y Z³, que pueden ser iguales o diferentes, se seleccionan independientemente de N y CR²; G¹ se selecciona de N y CR³; con una condición de que al menos uno de Z¹, Z³ y G¹ sea N; Q¹, Q², Q³ y Q⁴, que pueden ser iguales o diferentes, se seleccionan independientemente de N, CH y CR⁴; con una condición de que Q², Q³ y Q⁴ no sean N simultáneamente; W se selecciona de alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈alquilo C₁₋₈ sustituido o no sustituido, haloalquilo C₁₋₈ sustituido o no sustituido, hidroxialquilo C₁₋₈ sustituido o no sustituido, cicloalquilo C₃₋₁₂ sustituido o no sustituido y tetrahidrofurilo o tetrahidrofuranilo sustituido o no sustituido; R¹ se selecciona de alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈alquilo C₁₋₈ sustituido o no sustituido, haloalquilo C₁₋₈ sustituido o no sustituido, hidroxialquilo C₁₋₈ sustituido o no sustituido, cicloalquilo C₃₋₁₂ sustituido o no sustituido, arilo C₆₋₁₄ sustituido o no sustituido, heterociclilo de 3 - 15 miembros sustituido o no sustituido y heteroarilo de 5 - 14 miembros sustituido o no sustituido; cada aparición de R² y R³, que pueden ser iguales o diferentes, se selecciona independientemente de hidrógeno, halógeno, nitro, ciano, hidroxilo, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, haloalquilo C₁₋₈ sustituido o no sustituido, hidroxialquilo C₁₋₈ sustituido o no sustituido, cicloalquilo C₃₋₁₂ sustituido o no sustituido y cicloalquil C₃₋₈alquilo C₁₋₈ sustituido o no sustituido; en cada aparición, R⁴ se selecciona independientemente de halógeno, nitro, ciano, hidroxilo, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈alquilo C₁₋₈ sustituido o no sustituido, haloalquilo C₁₋₈ sustituido o no sustituido, hidroxialquilo C₁₋₈ sustituido o no sustituido y cicloalquilo C₃₋₁₂ sustituido o no sustituido y cicloalquilo C₃₋₈alquilo C₁₋₈ sustituido o no sustituido; en cada aparición, Rᶜ se selecciona independientemente de alquilo C₁₋₈ sustituido o no sustituido y aril C₆₋₁₄alquil C₁₋₈ sustituido o no sustituido; o RC y R¹, junto con el N al que están unidos, forman un anillo de morfolina; cada aparición de RX y Rʸ, que pueden ser iguales o diferentes, se seleccionan independientemente de hidrógeno, alquilo C₁₋₈ sustituido o no sustituido y aril C₆₋₁₄alquilo C₁₋₈ sustituido o no sustituido; y n es un entero que se encuentra en el intervalo de 1 a 4, ambos inclusive.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN372MU2012 | 2012-02-09 | ||
| US201261602227P | 2012-02-23 | 2012-02-23 | |
| IN1302MU2012 | 2012-04-24 | ||
| US201261645193P | 2012-05-10 | 2012-05-10 | |
| IN2576MU2012 | 2012-09-05 | ||
| US201261707838P | 2012-09-28 | 2012-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089939A1 true AR089939A1 (es) | 2014-10-01 |
Family
ID=48946104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100396 AR089939A1 (es) | 2012-02-09 | 2013-02-07 | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US9006257B2 (es) |
| AR (1) | AR089939A1 (es) |
| WO (1) | WO2013118071A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| WO2014130612A1 (en) | 2013-02-20 | 2014-08-28 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| BR112016023679A2 (pt) * | 2014-04-14 | 2017-08-15 | Jiangsu Hengrui Medicine Co | derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos |
| US20200347038A1 (en) | 2014-08-29 | 2020-11-05 | Russell Dahl | Quinolines that modulate serca and their use for treating disease |
| WO2016032569A1 (en) * | 2014-08-29 | 2016-03-03 | Celladon Corporation | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases |
| CN105237476A (zh) * | 2015-10-31 | 2016-01-13 | 高大元 | 一种4-氯-8-氨基喹啉的合成方法 |
| CN109688818A (zh) | 2016-09-08 | 2019-04-26 | 卡拉制药公司 | 治疗化合物的晶型及其用途 |
| EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| BR112019009529A2 (pt) | 2016-11-11 | 2019-07-30 | Bayer Animal Health Gmbh | novos derivados de quinolina |
| US11254661B2 (en) | 2017-08-04 | 2022-02-22 | Bayer Animal Health Gmbh | Quinoline derivatives for treating infections with helminths |
| KR20200090818A (ko) | 2017-11-22 | 2020-07-29 | 콘드리온 아이피 비.브이. | Mpges-1 억제제로서의 신규 화합물 |
| MX2020006185A (es) | 2017-12-15 | 2020-09-03 | Bayer Animal Health Gmbh | Proceso para la preparacion de derivados de quinolina. |
| CN112074514B (zh) | 2018-05-09 | 2024-10-29 | 礼蓝动物保健有限公司 | 新的喹啉衍生物 |
| PT3814347T (pt) | 2018-06-27 | 2023-07-18 | Bristol Myers Squibb Co | Compostos de naftiridinona úteis como ativadores de células t |
| HRP20231253T1 (hr) | 2018-06-27 | 2024-02-02 | Bristol-Myers Squibb Company | Supstituirani spojevi naftiridina korisni kao aktivatori t stanica |
| JP2021529830A (ja) * | 2018-07-02 | 2021-11-04 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | ラクテート増強化合物及びその使用 |
| BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| PL4045083T3 (pl) | 2019-10-18 | 2024-05-13 | Forty Seven, Inc. | Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN111018777B (zh) * | 2019-11-25 | 2021-02-12 | 武汉智顿科技发展有限公司 | 一种地喹氯铵的制备方法 |
| CN110963967B (zh) * | 2019-11-25 | 2021-02-12 | 武汉智顿科技发展有限公司 | 一种2-甲基-4-氨基喹啉的制备方法 |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CR20220303A (es) | 2019-12-24 | 2022-09-02 | Gilead Sciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
| PE20231067A1 (es) | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos |
| US12110294B2 (en) | 2020-05-01 | 2024-10-08 | Gilead Sciences, Inc. | CD73 compounds |
| US11730729B2 (en) | 2020-07-20 | 2023-08-22 | Neurodon Corporation | Quinolines that modulate SERCA and their use for treating disease |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| AU2022295990A1 (en) | 2021-06-18 | 2024-01-04 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| AU2022297373A1 (en) | 2021-06-23 | 2024-01-04 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN118139858A (zh) | 2021-10-28 | 2024-06-04 | 吉利德科学公司 | 吡地嗪-3(2h)-酮衍生物 |
| KR20240125012A (ko) | 2021-12-22 | 2024-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JPWO2023127883A1 (es) | 2021-12-28 | 2023-07-06 | ||
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| DK4245756T3 (da) | 2022-03-17 | 2024-10-21 | Gilead Sciences Inc | Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN115124463B (zh) * | 2022-07-01 | 2023-11-28 | 浙江工业大学 | 取代喹啉类化合物及其制备方法和应用 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2410905T3 (es) | 2004-12-17 | 2013-07-03 | Merck Canada Inc. | 2-(Fenil o heterociclo)-1H-fenantro[9,10-d]imidazoles como inhibidores de la MPGES-1 |
| US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) * | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| WO2012110860A1 (en) | 2011-02-17 | 2012-08-23 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| EP2495244A1 (en) * | 2011-03-02 | 2012-09-05 | NovaSaid AB | Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors |
-
2013
- 2013-02-07 WO PCT/IB2013/051004 patent/WO2013118071A1/en active Application Filing
- 2013-02-07 US US13/761,937 patent/US9006257B2/en not_active Expired - Fee Related
- 2013-02-07 AR ARP130100396 patent/AR089939A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130210844A1 (en) | 2013-08-15 |
| US9006257B2 (en) | 2015-04-14 |
| WO2013118071A1 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089939A1 (es) | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 | |
| AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR091437A1 (es) | COMPUESTOS DE TRIAZOLONA COMO INHIBIDORES DE mPGES-1 | |
| AR112834A1 (es) | Derivados de rapamicina | |
| EA201291409A1 (ru) | Производные индолизина, способ их получения и их терапевтическое применение | |
| SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| CO7400871A2 (es) | Compuestos de piridilo sustituidos con heteroarilo útiles como moduladores de cinasa | |
| AR094214A1 (es) | Inhibidores de la quinasa que regula la señal de la apoptosis | |
| MD20180040A2 (ro) | Inhibitori ai virusului hepatic C | |
| WO2015004566A3 (en) | Liquid bisacylphosphine oxide photoinitiator | |
| CR10784A (es) | Nuevos derivados de aminopirimidina como inhibidores de plki | |
| EA201890522A1 (ru) | Способ получения противогрибковых соединений | |
| MY159870A (en) | Piperazine compound capable of inhibiting prostaglandin d synthase | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| AR086198A1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen | |
| MY150778A (en) | Fused heterocyclic compound | |
| JP2015527363A5 (es) | ||
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |